N-Methyl-1-(3-methyloxetan-3-yl)methanamine, 95.0%, 5g

6-Bromo-8-ethyl-2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one, 98%, 100mg

4-(2-oxo-1,2-dihydropyridin-1-yl)butanoic acid, 95.0%, 1g

CYCLOBUTANAMINE, 3-(4-METHYLPHENOXY)-, HCL (1:1), TRANS-, 95.0%, 1g

N,N-Diisopropyléthylamine, PEPTIPURE®, min 99,5 %, pour la synthèse peptidique, 2,5 l

6-Bromoquinoline, 98.0%, 100g

(S)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetic acid, 97%, 1g

2-Chlorobenzenethiol>97.0%(GC)25g

1-Ethyl-3-methylimidazolium Methyl Sulfate>98.0%(HPLC)5g

1-(tert-Butoxycarbonylamino)cyclopentanecarboxylic Acid>98.0%(GC)(T)5g

4-BROMO-3-CYCLOPROPYL-5-METHYL-1H-PYRAZOLE, 95%, 100mg

4-methoxy-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol, 95.0%, 10g

AVANAFIL, 95%, 250mg